Novartis Refocuses Shanghai Research Institute on Drug Development, not Discovery

Novartis plans big changes to its large Shanghai research institute, refocusing the facility on drug development rather than drug discovery. According to a company official, the China facility has been successful at discovering drug candidates, but after "China's explosion of talent," Novartis needs development services, for molecules discovered both in and out of China. The company plans to file 50 new drug applications in China, and it will also strengthen its business development team as it builds relationships with young China biopharmas. More details.... Stock Symbol: (NYSE: NVS) Share this with colleagues: // //